首页 > 最新文献

International Journal of Tuberculosis and Lung Disease最新文献

英文 中文
Geographic information systems analysis to focus TB screening among people born in endemic countries. 地理信息系统分析,重点对流行国家出生的人进行结核病筛查。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0471
S Zavala, M C Kiritsy, G M Cox, A Ahmed, J E Stout, N A Turner

BACKGROUNDGeographic information systems may help focus TB screening and treatment efforts to populations in greatest need, such as people born in endemic countries (PBEC).DESIGN/METHODSNorth Carolina USA census and TB surveillance data were used to examine the relationship between the population proportion of PBEC and incident TB cases in the subsequent 5-year period by census tract. Census tract population:incident TB ratios for thresholds of PBEC were used to measure screening efficiency.RESULTSOf 3,290 PBEC TB cases, 2,764 (84%) had a mappable address. The proportion of census tract PBEC during 2006-2010 was strongly associated with incident TB in that tract in 2011-2015 (p < 0.001). Thresholds of 6%, 12%, and 19% PBEC in a tract during 2006-2010 as cutoffs for screening would have detected 75%, 50%, and 25% of incident TB cases in 2011-2015 with respective population:incident TB ratios of 11,840, 6,864, and 5,524 population/case. The same thresholds using 2011-2015 census data would have detected 75%, 50%, and 25% of incident TB cases during 2016-2018 with population:incident TB ratios of 17,804, 10,807, and 7,031 population/case.CONCLUSIONCensus tract demographics are a simple and powerful tool to focus targeted testing and treatment of latent TB in areas likely to have incident TB disease..

地理信息系统可能有助于将结核病筛查和治疗工作的重点放在最需要的人群上,例如在流行国家出生的人(PBEC)。设计/方法采用美国北卡罗莱纳州人口普查和结核病监测数据,通过人口普查区研究PBEC人口比例与随后5年结核病发病率之间的关系。人口普查区人口:PBEC阈值的发病率用于衡量筛查效率。结果3290例PBEC结核病例中,有2764例(84%)有可映射地址。2006-2010年人口普查区PBEC的比例与2011-2015年该地区的结核病发病率密切相关(p < 0.001)。在2006-2010年期间,一个地区6%、12%和19%的PBEC阈值作为筛查的截止值,将在2011-2015年分别检出75%、50%和25%的结核病病例:结核病发病率分别为11840、6864和5524人/例。使用2011-2015年人口普查数据的相同阈值将检测到2016-2018年期间75%、50%和25%的结核病病例,人口:结核病发病率为17,804、10,807和7,031人/例。结论人口普查区的人口统计数据是一种简单有效的工具,可以在可能发生结核病的地区有针对性地检测和治疗潜伏性结核病。
{"title":"Geographic information systems analysis to focus TB screening among people born in endemic countries.","authors":"S Zavala, M C Kiritsy, G M Cox, A Ahmed, J E Stout, N A Turner","doi":"10.5588/ijtld.24.0471","DOIUrl":"10.5588/ijtld.24.0471","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>Geographic information systems may help focus TB screening and treatment efforts to populations in greatest need, such as people born in endemic countries (PBEC).</sec><sec><title>DESIGN/METHODS</title>North Carolina USA census and TB surveillance data were used to examine the relationship between the population proportion of PBEC and incident TB cases in the subsequent 5-year period by census tract. Census tract population:incident TB ratios for thresholds of PBEC were used to measure screening efficiency.</sec><sec><title>RESULTS</title>Of 3,290 PBEC TB cases, 2,764 (84%) had a mappable address. The proportion of census tract PBEC during 2006-2010 was strongly associated with incident TB in that tract in 2011-2015 (<i>p</i> < 0.001). Thresholds of 6%, 12%, and 19% PBEC in a tract during 2006-2010 as cutoffs for screening would have detected 75%, 50%, and 25% of incident TB cases in 2011-2015 with respective population:incident TB ratios of 11,840, 6,864, and 5,524 population/case. The same thresholds using 2011-2015 census data would have detected 75%, 50%, and 25% of incident TB cases during 2016-2018 with population:incident TB ratios of 17,804, 10,807, and 7,031 population/case.</sec><sec><title>CONCLUSION</title>Census tract demographics are a simple and powerful tool to focus targeted testing and treatment of latent TB in areas likely to have incident TB disease.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"159-163"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of community awareness, screening, diagnosis, and treatment campaigns on TB care in Uganda. 乌干达社区意识、筛查、诊断和治疗运动对结核病护理的影响。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0488
R Mulebeke, C Chemutai, I Mubangizi, M Balina, J E Obwalatum, C Senyimba, J Izudi

SETTINGEight districts in central Uganda with 105 health facilities.OBJECTIVETo evaluate the effectiveness of the community awareness, screening, testing, diagnosis, and treatment (CAST-TB) campaigns on the number of people screened for, presumed to have, and diagnosed with TB disease.DESIGNWe designed a quasi-experimental study and utilised Bayesian Structural Time-Series analysis for counterfactual predictions over 24 months (12 months before vs 12 months during intervention). The intervention was the CAST-TB campaigns. The outcomes included the number of people screened for, presumed to have, and diagnosed with TB disease.RESULTSThe intervention led to a 36% (95% credible interval [CrI] 8.4-65, P = 0.005) increase in the number of people screened for TB disease (1,194,257 observed vs 875,211 predicted), a 29% (95% CrI 5.3-52, P = 0.01) increase in the number of people presumed to have TB disease (25,784 observed vs 19,997 predicted), and a 49% (95% CrI 25-75) increase in the number of people diagnosed with TB disease (2,566 observed vs 1,719 counterfactual).CONCLUSIONCAST-TB campaigns improved the number of people screened for, presumed to have, and diagnosed with TB disease in central Uganda, supporting scale-up efforts nationally and across sub-Saharan Africa where such indicators are suboptimal..

目标评估社区宣传、筛查、检测、诊断和治疗(CAST-TB)活动对结核病筛查、推测和诊断人数的影响。设计我们设计了一项准实验研究,并利用贝叶斯结构时间序列分析法对 24 个月(干预前 12 个月与干预期间 12 个月)内的反事实预测进行了分析。干预措施是 CAST-TB 运动。结果干预使结核病筛查人数增加了 36%(95% 可信区间 [CrI] 8.4-65,P = 0.005)(观察到的人数为 1,194,257 人,而预测的人数为 875,211 人),结核病筛查人数增加了 29%(95% 可信区间 [CrI] 5.3-52,P = 0.01),结核病筛查人数增加了 30%(95% 可信区间 [CrI] 8.4-65,P = 0.005),结核病筛查人数增加了 30%(95% 可信区间 [CrI] 8.4-65,P = 0.005),结核病筛查人数增加了 30%(95% 可信区间 [CrI] 8.4-65,P = 0.005)。结论CAST-TB运动提高了乌干达中部地区肺结核病筛查、推测和诊断的人数,支持了全国以及撒哈拉以南非洲地区的推广工作,因为这些地区的此类指标并不理想。
{"title":"Effect of community awareness, screening, diagnosis, and treatment campaigns on TB care in Uganda.","authors":"R Mulebeke, C Chemutai, I Mubangizi, M Balina, J E Obwalatum, C Senyimba, J Izudi","doi":"10.5588/ijtld.24.0488","DOIUrl":"10.5588/ijtld.24.0488","url":null,"abstract":"<p><p><sec><title>SETTING</title>Eight districts in central Uganda with 105 health facilities.</sec><sec><title>OBJECTIVE</title>To evaluate the effectiveness of the community awareness, screening, testing, diagnosis, and treatment (CAST-TB) campaigns on the number of people screened for, presumed to have, and diagnosed with TB disease.</sec><sec><title>DESIGN</title>We designed a quasi-experimental study and utilised Bayesian Structural Time-Series analysis for counterfactual predictions over 24 months (12 months before vs 12 months during intervention). The intervention was the CAST-TB campaigns. The outcomes included the number of people screened for, presumed to have, and diagnosed with TB disease.</sec><sec><title>RESULTS</title>The intervention led to a 36% (95% credible interval [CrI] 8.4-65, <i>P</i> = 0.005) increase in the number of people screened for TB disease (1,194,257 observed vs 875,211 predicted), a 29% (95% CrI 5.3-52, <i>P</i> = 0.01) increase in the number of people presumed to have TB disease (25,784 observed vs 19,997 predicted), and a 49% (95% CrI 25-75) increase in the number of people diagnosed with TB disease (2,566 observed vs 1,719 counterfactual).</sec><sec><title>CONCLUSION</title>CAST-TB campaigns improved the number of people screened for, presumed to have, and diagnosed with TB disease in central Uganda, supporting scale-up efforts nationally and across sub-Saharan Africa where such indicators are suboptimal.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"178-183"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glutathione and N-acetylcysteine in TB management. 谷胱甘肽和n -乙酰半胱氨酸在结核病管理中的作用。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0604
M J Nasiri, N Khoshdel, V Venketaraman

BACKGROUNDTB remains a major global health challenge. Glutathione (GSH) and N-acetylcysteine (NAC) have been proposed as adjunctive therapies with potential clinical and immunomodulatory benefits. This systematic review aims to evaluate the efficacy, safety, and immunomodulatory effects of GSH and NAC as adjunctive therapies in TB management.METHODSPubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched until October 15, 2024. We included studies assessing the efficacy of GSH and NAC in TB management, focusing on clinical outcomes such as lung function recovery, sputum conversion, hepatoprotection, and immune response modulation. The quality of the studies was assessed using the Cochrane Risk of Bias tool.RESULTSEight controlled trials were included. GSH and NAC significantly improved lung function accelerated sputum conversion, and provided hepatoprotective effects. GSH, particularly in its liposomal form, enhanced immune responses by modulating cytokine levels and reducing oxidative stress. Most adverse effects reported were mild and manageable, indicating a favourable safety profile for both agents.CONCLUSIONSGSH and NAC show promise as adjunctive therapies in TB management, demonstrating improvements in lung function, sputum conversion, and hepatoprotection while also enhancing immune responses..

背景:结核病仍然是一项重大的全球卫生挑战。谷胱甘肽(GSH)和n -乙酰半胱氨酸(NAC)已被认为是具有潜在临床和免疫调节益处的辅助疗法。本系统综述旨在评估GSH和NAC作为结核病辅助治疗的有效性、安全性和免疫调节作用。方法检索spubmed /MEDLINE、Embase和Cochrane CENTRAL至2024年10月15日。我们纳入了评估GSH和NAC在结核病治疗中的疗效的研究,重点关注临床结果,如肺功能恢复、痰转化、肝保护和免疫反应调节。使用Cochrane偏倚风险工具评估研究的质量。结果纳入8项对照试验。GSH和NAC可显著改善肺功能,加速痰转化,并具有保肝作用。谷胱甘肽,特别是其脂质体形式,通过调节细胞因子水平和减少氧化应激来增强免疫反应。报告的大多数不良反应是轻微和可控的,表明两种药物的良好安全性。结论:sgsh和NAC作为结核病治疗的辅助疗法,显示出改善肺功能、痰转化和肝保护的潜力,同时也增强了免疫反应。
{"title":"Glutathione and <i>N</i>-acetylcysteine in TB management.","authors":"M J Nasiri, N Khoshdel, V Venketaraman","doi":"10.5588/ijtld.24.0604","DOIUrl":"10.5588/ijtld.24.0604","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>TB remains a major global health challenge. Glutathione (GSH) and <i>N</i>-acetylcysteine (NAC) have been proposed as adjunctive therapies with potential clinical and immunomodulatory benefits. This systematic review aims to evaluate the efficacy, safety, and immunomodulatory effects of GSH and NAC as adjunctive therapies in TB management.</sec><sec><title>METHODS</title>PubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched until October 15, 2024. We included studies assessing the efficacy of GSH and NAC in TB management, focusing on clinical outcomes such as lung function recovery, sputum conversion, hepatoprotection, and immune response modulation. The quality of the studies was assessed using the Cochrane Risk of Bias tool.</sec><sec><title>RESULTS</title>Eight controlled trials were included. GSH and NAC significantly improved lung function accelerated sputum conversion, and provided hepatoprotective effects. GSH, particularly in its liposomal form, enhanced immune responses by modulating cytokine levels and reducing oxidative stress. Most adverse effects reported were mild and manageable, indicating a favourable safety profile for both agents.</sec><sec><title>CONCLUSIONS</title>GSH and NAC show promise as adjunctive therapies in TB management, demonstrating improvements in lung function, sputum conversion, and hepatoprotection while also enhancing immune responses.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"171-177"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug susceptibility testing for TB using the Xpert MTB/XDR assay on stool specimens. 使用Xpert MTB/XDR法对粪便标本进行结核病药敏试验。
IF 3.1 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0366
W Khumalo, N Maphalala, D Mulengwa, M Ziyane, D B Sibandze, S Niemann, V Dreyer, A Seeger, M Madison, T Ness, T Jele, A L Garcia-Basteiro, G Maphalala, A R DiNardo, A M Mandalakas, A Kay
{"title":"Drug susceptibility testing for TB using the Xpert MTB/XDR assay on stool specimens.","authors":"W Khumalo, N Maphalala, D Mulengwa, M Ziyane, D B Sibandze, S Niemann, V Dreyer, A Seeger, M Madison, T Ness, T Jele, A L Garcia-Basteiro, G Maphalala, A R DiNardo, A M Mandalakas, A Kay","doi":"10.5588/ijtld.24.0366","DOIUrl":"10.5588/ijtld.24.0366","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"189-192"},"PeriodicalIF":3.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes. 糖尿病患者抗结核二线药物的人群药代动力学和剂量评价。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0481
J Cao, G Shao, H Zhong, L Davies Forsman, S Wang, S Dong, X Li, Z Ning, H Cao, Y Hu

BACKGROUNDTo evaluate currently recommended dosage using the population pharmacokinetics (PK) of bedaquiline (BDQ), clofazimine, cycloserine, linezolid (LZD) and moxifloxacin (MFX) in patients with multidrug-resistant TB (MDR-TB) and type II diabetes mellitus (DM).METHODSA prospective multi-centre PK study was conducted in China between 2016 and 2019. Population PK models were developed using nonlinear mixed-effect analyses based on the blood samples collected by rich sampling. The probability of target attainment (PTA) analysis was estimated using the Monte Carlo simulation.RESULTSA total of 1,450 plasma samples were collected from 58 participants with DM. Simulations showed that the WHO-recommended regimens of LZD (600 mg daily) and MFX (400 mg daily) achieved > 90% PTA for M. tuberculosis isolates with MICs below 0.50 and 0.25 mg/L, respectively. The currently recommended BDQ regimen (400 mg daily for 2 weeks, followed by 200 mg thrice weekly) might fail to achieve >90% PTA at an MIC of 0.06 mg/L or higher.CONCLUSIONThe population PK models for the five second-line drugs were established in Chinese patients with MDR-TB and DM. The model-based dosage evaluation showed that dosing adjustments may be necessary for isolates with borderline resistance levels..

背景:利用贝达喹啉(BDQ)、氯法齐明、环丝氨酸、利奈唑胺(LZD)和莫西沙星(MFX)在耐多药结核病(MDR-TB)和II型糖尿病(DM)患者中的群体药代动力学(PK)来评估目前推荐的剂量。方法2016 - 2019年在中国进行前瞻性多中心PK研究。基于富采样采集的血液样本,采用非线性混合效应分析建立种群PK模型。利用蒙特卡罗模拟估计了目标实现概率(PTA)分析。结果共收集了58名DM患者的1450份血浆样本。模拟结果显示,who推荐的LZD (600 mg/L)和MFX (400 mg/L)方案对mic低于0.50和0.25 mg/L的结核分枝杆菌分离株的PTA分别达到了90%以上。目前推荐的BDQ方案(每天400毫克,连续2周,随后每周3次,每次200毫克)在MIC为0.06毫克/升或更高时可能无法达到bbb90 %的PTA。结论在中国耐多药结核病和糖尿病患者中建立了5种二线药物的群体PK模型,基于模型的剂量评估表明,对于处于临界耐药水平的分离株,可能需要调整剂量。
{"title":"Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes.","authors":"J Cao, G Shao, H Zhong, L Davies Forsman, S Wang, S Dong, X Li, Z Ning, H Cao, Y Hu","doi":"10.5588/ijtld.24.0481","DOIUrl":"10.5588/ijtld.24.0481","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>To evaluate currently recommended dosage using the population pharmacokinetics (PK) of bedaquiline (BDQ), clofazimine, cycloserine, linezolid (LZD) and moxifloxacin (MFX) in patients with multidrug-resistant TB (MDR-TB) and type II diabetes mellitus (DM).</sec><sec><title>METHODS</title>A prospective multi-centre PK study was conducted in China between 2016 and 2019. Population PK models were developed using nonlinear mixed-effect analyses based on the blood samples collected by rich sampling. The probability of target attainment (PTA) analysis was estimated using the Monte Carlo simulation.</sec><sec><title>RESULTS</title>A total of 1,450 plasma samples were collected from 58 participants with DM. Simulations showed that the WHO-recommended regimens of LZD (600 mg daily) and MFX (400 mg daily) achieved > 90% PTA for <i>M. tuberculosis</i> isolates with MICs below 0.50 and 0.25 mg/L, respectively. The currently recommended BDQ regimen (400 mg daily for 2 weeks, followed by 200 mg thrice weekly) might fail to achieve >90% PTA at an MIC of 0.06 mg/L or higher.</sec><sec><title>CONCLUSION</title>The population PK models for the five second-line drugs were established in Chinese patients with MDR-TB and DM. The model-based dosage evaluation showed that dosing adjustments may be necessary for isolates with borderline resistance levels.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"164-170"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Authors: addressing concerns to ensure effective TB preventive therapy. 回复作者:解决问题,确保有效的结核病预防治疗。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.25.0077
R Borse, B Randive, S Mattoo, P Malik, H Solanki, A Gupta, R E Chaisson, V Mave, N Suryavanshi
{"title":"Reply to Authors: addressing concerns to ensure effective TB preventive therapy.","authors":"R Borse, B Randive, S Mattoo, P Malik, H Solanki, A Gupta, R E Chaisson, V Mave, N Suryavanshi","doi":"10.5588/ijtld.25.0077","DOIUrl":"10.5588/ijtld.25.0077","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"196-197"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contribution of post-infectious bronchiolitis obliterans to non-cystic fibrosis bronchiectasis in children. 儿童感染后闭塞性细支气管炎对非囊性纤维化支气管扩张的贡献。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0544
A Gie, C Le Roux, M M van der Zalm, C Jacobs, N Parker, E Eber, P Goussard

BACKGROUNDPost-infectious bronchiolitis obliterans (PIBO) is a complication of severe childhood respiratory infection resulting in small airway injury, bronchiectasis, and prolonged respiratory consequences. Risk factors for PIBO and PIBO-associated bronchiectasis are unclear.METHODSThis retrospective study identified all children with PIBO at a South African tertiary hospital between 1 January 2016 and 31 December 2022. The clinical characteristics, chest CT findings, and details of prior hospitalisation for respiratory infection were collected, and the characteristics of those with and without bronchiectasis were compared.RESULTSA total of 59 children were included (median age at primary lung insult: 10 months, IQR 6-17; median age at PIBO diagnosis: 16 months, IQR 11-28). Twenty-three had comorbidities, most frequently premature birth (30.5%) and HIV infection (6.8%). The most common pathogen was adenovirus (n = 41; 69.5%). At initial lung insult, 19 (32.2%) required mechanical ventilation. Mosaic attenuation on the chest CT was present in all. Thirty-three (55.9%) had bronchiectasis. The clinical characteristics, ventilation, causative pathogen, and comorbidity were similar in those with and without bronchiectasis.CONCLUSIONBronchiectasis occurs frequently in paediatric PIBO and is present within months of initial respiratory insult with no identified risk factors. Premature birth is common and may contribute to PIBO development..

背景:感染后闭塞性细支气管炎(PIBO)是儿童严重呼吸道感染的并发症,可导致小气道损伤、支气管扩张和延长呼吸后果。PIBO和PIBO相关支气管扩张的危险因素尚不清楚。方法回顾性研究选取2016年1月1日至2022年12月31日在南非一家三级医院的所有PIBO患儿。收集患者的临床特征、胸部CT表现和既往呼吸道感染住院细节,并比较支气管扩张组和非支气管扩张组的特征。结果共纳入59例患儿(原发性肺损伤时中位年龄:10个月,IQR 6-17;PIBO诊断时的中位年龄:16个月,IQR 11-28)。23人有合并症,最常见的是早产(30.5%)和艾滋病毒感染(6.8%)。最常见的病原体为腺病毒(n = 41;69.5%)。在初始肺损伤时,19例(32.2%)需要机械通气。胸部CT上均出现马赛克衰减。33例(55.9%)有支气管扩张。支气管扩张组与非支气管扩张组的临床特征、通气情况、致病菌及合并症相似。结论:支气管扩张在小儿PIBO中常见,并在初始呼吸损伤后几个月内出现,无明确的危险因素。早产是常见的,可能有助于PIBO的发展。
{"title":"Contribution of post-infectious bronchiolitis obliterans to non-cystic fibrosis bronchiectasis in children.","authors":"A Gie, C Le Roux, M M van der Zalm, C Jacobs, N Parker, E Eber, P Goussard","doi":"10.5588/ijtld.24.0544","DOIUrl":"10.5588/ijtld.24.0544","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>Post-infectious bronchiolitis obliterans (PIBO) is a complication of severe childhood respiratory infection resulting in small airway injury, bronchiectasis, and prolonged respiratory consequences. Risk factors for PIBO and PIBO-associated bronchiectasis are unclear.</sec><sec><title>METHODS</title>This retrospective study identified all children with PIBO at a South African tertiary hospital between 1 January 2016 and 31 December 2022. The clinical characteristics, chest CT findings, and details of prior hospitalisation for respiratory infection were collected, and the characteristics of those with and without bronchiectasis were compared.</sec><sec><title>RESULTS</title>A total of 59 children were included (median age at primary lung insult: 10 months, IQR 6-17; median age at PIBO diagnosis: 16 months, IQR 11-28). Twenty-three had comorbidities, most frequently premature birth (30.5%) and HIV infection (6.8%). The most common pathogen was adenovirus (<i>n</i> = 41; 69.5%). At initial lung insult, 19 (32.2%) required mechanical ventilation. Mosaic attenuation on the chest CT was present in all. Thirty-three (55.9%) had bronchiectasis. The clinical characteristics, ventilation, causative pathogen, and comorbidity were similar in those with and without bronchiectasis.</sec><sec><title>CONCLUSION</title>Bronchiectasis occurs frequently in paediatric PIBO and is present within months of initial respiratory insult with no identified risk factors. Premature birth is common and may contribute to PIBO development.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"153-158"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of different genotyping methods to estimate TB transmission in the United States, 2020-2021. 使用不同基因分型方法估计2020-2021年美国结核病传播
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0464
K R Schildknecht, L S Cowen, J E Posey, S Talarico, M B Haddad, J M Wortham, J S Kammerer
{"title":"Use of different genotyping methods to estimate TB transmission in the United States, 2020-2021.","authors":"K R Schildknecht, L S Cowen, J E Posey, S Talarico, M B Haddad, J M Wortham, J S Kammerer","doi":"10.5588/ijtld.24.0464","DOIUrl":"10.5588/ijtld.24.0464","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"193-195"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TB as a risk factor for severe COVID-19 mortality. 结核病是COVID-19严重死亡的一个危险因素。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0503
I C Borges, F M Lino, A Luna-Muschi, M N Litvoc, M I B F Lopes, H R Higashino, Á F da Costa, R H M Pereira, H I Nakaya, J D A de Araújo, G M Orlandi, M J P Rújula, T R M P Carvalhanas, L Nielsen, C M Minto, E C Sabino, S F Costa, O Ranzani
{"title":"TB as a risk factor for severe COVID-19 mortality.","authors":"I C Borges, F M Lino, A Luna-Muschi, M N Litvoc, M I B F Lopes, H R Higashino, Á F da Costa, R H M Pereira, H I Nakaya, J D A de Araújo, G M Orlandi, M J P Rújula, T R M P Carvalhanas, L Nielsen, C M Minto, E C Sabino, S F Costa, O Ranzani","doi":"10.5588/ijtld.24.0503","DOIUrl":"https://doi.org/10.5588/ijtld.24.0503","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"186-188"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful rechallenge of rifabutin in rifampicin-induced thrombocytopenia during TB treatment. 在结核病治疗期间利福平诱导的血小板减少症中利福丁的成功再挑战。
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-31 DOI: 10.5588/ijtld.24.0508
R R Nelson, V J Louw, B Curtis, J Peter
{"title":"Successful rechallenge of rifabutin in rifampicin-induced thrombocytopenia during TB treatment.","authors":"R R Nelson, V J Louw, B Curtis, J Peter","doi":"10.5588/ijtld.24.0508","DOIUrl":"https://doi.org/10.5588/ijtld.24.0508","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"184-185"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Tuberculosis and Lung Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1